Accessibility Menu
Notable Labs logo

Notable Labs(OTC) NTBL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-100%
5 YearN/A
1 Year-99%
1 Month+0%
N/A
Notable Labs last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-28
Notable Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-21
1 month+0%USD 0.002026-07-27
3 month+0%USD 0.002026-05-27
Year to date-99%USD 0.002025-12-31
1 year-99%USD 0.002025-08-28
Since inception-100%USD 4.452023-10-17

Notable Labs Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.00K

Net Income (TTM)

-$12.50M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 12, 2024

NTBL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Notable Labs

Notable Labs, Ltd. is a clinical-stage therapeutic platform company focused on developing predictive, personalized treatments for cancer patients. Utilizing its proprietary Predictive Precision Medicines Platform (PPMP), the company aims to enhance the clinical development process by identifying patients likely to respond favorably to specific therapies.

Products and Services
  • Predictive Precision Medicines Platform (PPMP) for personalized cancer treatment
  • Volasertib, a PLK-1 inhibitor targeting acute myeloid leukemia
  • Fosciclopirox, a prodrug aimed at treating acute myeloid leukemia
Growth Outlook
  • Recent quarterly revenue increased to $2,000 from $1,000
  • Cash and cash equivalents stood at $4.09 million as of June 30, 2024
  • Current ratio of 5.65 indicates strong liquidity position
Financial Highlights
  • Net income for Q2 2024 was -$5.22 million, reflecting ongoing investment in R&D
  • Operating expenses totaled $5.32 million in Q2 2024, driven by R&D and administrative costs
  • Cash flow from operating activities was -$3.71 million in Q2 2024
Notable Labs, Ltd. operates in the biotechnology sector, with a focus on innovative cancer therapies. The company's PPMP allows for virtual testing of potential treatments, which can significantly expedite the identification of effective therapies for patients. The development pipeline includes promising candidates like Volasertib and Fosciclopirox, which target critical forms of leukemia. The growth outlook appears positive, with recent revenue increases and a solid liquidity position. However, the company continues to face challenges, as indicated by its net income and operating expenses. The focus on research and development is expected to drive future growth, although it currently results in significant losses. Investors may find the company's innovative approach and potential for future success appealing, despite the current financial challenges.
AI Generated • Aug 15, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Thomas A. Bock, MD, MBA

Website

www.notablelabs.com

Headquarters

Or-Yehuda, 60376, IL

NTBL Financials

Key Financial Metrics (TTM)

Gross Margin

36.45%

Operating Margin

-4728.06%

Net Income Margin

-3633.55%

Return on Equity

-59.97%

Return on Capital

-85.40%

Return on Assets

-57.64%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$63.00K

Operating Income

-$12.84M

EBITDA

-$14.87M

Operating Cash Flow

-$11.26M

Capital Expenditure

-$45.00K

Free Cash Flow

-$11.30M

Cash & ST Invst.

$4.09M

Total Debt

$1.80M

Notable Labs Performance Analysis

Notable Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 768,000N/A
20222022-12-31USD 658,000-14.3%
Notable Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q12024-03-31N/A
Q22024-06-30100.0%
Notable Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -15.78N/A
20222022-12-31USD -14.58-7.6%
Notable Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-3127.4%
Q22023-06-3067.2%
Q12024-03-31N/A
Q22024-06-30-31.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$2.00K

N/A

Gross Profit

-$62.00K

N/A

Gross Margin

-31.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

16

N/A

Net Income

-$5.22M

-59.5%

EBITDA

-$5.32M

-63.6%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$4.09M

-80.6%

Total Debt

$1.80M

+218.3%

Accounts Receivable

$184.00K

+80.4%

Inventory

$0.00

N/A

Long Term Debt

$1.25M

N/A

Short Term Debt

$546.00K

-3.2%

Return on Assets

-57.64%

N/A

Return on Invested Capital

-87.23%

N/A

Free Cash Flow

-$3.72M

+40.9%

Operating Cash Flow

-$3.71M

+41.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTNPalatin Technologies, Inc.
$9.99-4.68%
NOVNNovan, Inc.
$0.09-24.84%
BPTSBiophytis S.A.
$8.22-13.47%
PLXPPLx Pharma Inc.
$0.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About NTBL

What is the current price of Notable Labs?

Notable Labs is trading at N/A per share.

What is the 52-week range for Notable Labs?

Over the past 52 weeks, Notable Labs has traded between N/A and N/A.

How much debt does Notable Labs have?

As of the most recent reporting period, Notable Labs reported total debt of $564.00K.

How much cash does Notable Labs have on hand?

Notable Labs reported $18.03M in cash and cash equivalents in its most recent financial results.

What is Notable Labs’s dividend yield?

Notable Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services